(Reuters)
- AstraZeneca Plc said on Wednesday an advisory committee of the U.S.
Centers for Disease Control and Prevention recommended the use of its
FluMist Quadrivalent vaccine in the upcoming flu season, reversing its
earlier position.
In
2016, the agency advised doctors not to use the nasal spray citing data
that demonstrated it was not effective at preventing influenza.
(http://reut.rs/2sJavQ5)
The
latest recommendation follows results from a U.S. study in young
children that showed vaccines containing a 2017-2018 strain of H1N1 flu
virus performed better than the 2015-2016 strain that had shown
decreased effectiveness, AstraZeneca said.
The
announcement arrives in the midst of the most severe flu season the
country has experienced in decades. As of Feb. 3, 63 infants died this
season, the CDC reported earlier, adding outbreaks were likely to linger
for several weeks and cause more deaths.
The company said limited quantities of the vaccine continue to be available for the current season.
Source: Yahoo News
Hello, my name is Jack Sparrow. I'm a 50 year old self-employed Pirate from the Caribbean.
No comments:
Post a Comment